

Interface and Formulary Update - Issue 38

September and October 2025

Key messages from September and October 2025 TAG meetings - (ratified by Medicines Optimisation Programme Board)

Commissioning Review – AMBER INITIATE and AMBER ADVICE review

- Some TAG drugs have changed from original **ADVICE** to **AMBER INITIATE** following recent traffic light classification review
- This is not a change to existing commissioning arrangements.
- Aim is to provide clarity and support to primary care regarding who should initiate and how long specialist should retain

Commissioning Review - Aspirin for pregnant people aged 16 years and older at risk of pre-eclampsia as outlined in [NICE NG133](#)

- Aspirin should be taken daily by 'at risk' patients from week 12 of pregnancy up to 36 weeks / delivery.
- Women are seen before 10 weeks and only need aspirin from 12 weeks
- **AMBER ADVICE** - GPs would be asked to prescribe following midwife / maternity services recommendation

Formulary Review - Enalto® (Escitalopram oxalate orodispersible tabs)

- **GREEN - primary care initiation**
- Only if patient has swallowing problem

Pathway Review - Pizotifen for use in migraine prophylaxis

- **GREEN - primary care initiation**
- Pathway to be updated as appropriate
- Alternative (after first line options such as propranolol and amitriptyline) within the migraine pathway

Formulary Review - Relugolix with estradiol and norethisterone acetate (Ryeqo) for endometriosis

- **AMBER INITIATE**
- Specialist to provide first month in line with other pathway options
- Third line option

Formulary Review – Allergic Rhinitis and Sublingual Immunotherapy

- Combination nasal sprays amended to **GREEN - Can be initiated and prescribed in any care setting, within licensed indications**
- [Acarizax](#), [Grazax](#) and [Itulazax](#) have **AMBER INITIATE** classifications and guidance documents to support prescribers

Formulary Review - Budenofalk 4mg Suppository for acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adults

- **AMBER ADVICE**
- Specialist to provide information about length of treatment

Shared Care Updates

- [Naltrexone](#) for Abstinence in Alcohol Use Disorder – contact details updated
- [Low Molecular Weight Heparin \(LMWH\)](#) – routine updates listed at end of document
- [Mercaptopurine](#) – clarified that shared care agreement only covers adults
- [Patient Choice & Shared Care Prescribing](#) – New document

Formulary and Guidance Updates

Guidance Updates

- [Hidradenitis Suppurativa](#) – new document to support prescribers
- [Tirzepatide](#) - updates to local documents
- Testosterone menopause – [Prescribing Guidance](#) and [Patient Information](#)
- Guidance for appropriate prescribing for [phenylketonuria \(PKU\)](#)
- [Dry Eye](#) Pathway
- [Diabetes](#) updates
 - Key Message – [Lancets](#)
 - [Lancets](#) spreadsheet
 - [Blood Glucose Test Strips](#) spreadsheet
- [Vitamin B12](#) Deprescribing Flowchart
- [Tracheostomy and Laryngectomy](#) Fair Use Policy v3.0

Formulary updates

- **Pramipexole** Immediate Release and Prolonged Release – Use in Parkinson's Disease
 - IR – **AMBER ADVICE**. Requirement for Consultant initiation has been removed
 - PR – **AMBER ADVICE** for those patients initiated before March 2011. No new patients to be initiated on Pramipexole PR after March 2011. Seek advice from Medicines Optimisation team if required as a last resort when all other formulary options have been unsuccessful.
- **Phosphate enemas** - confirmed that **Cleen** is best-value preparation to use in primary care.
- **Femsoft** urethral insert - **BLACK – Not Commissioned**
- **Uricap** female soft silicone cap - **BLACK – Not Commissioned**
- **Cycloserine** 250mg capsules – **RED – Hospital Only**
- **Hyperseal Washers** - **BLACK Not Commissioned** for seals with manuka honey

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

RED

TA1077 – July 2025 - Nemolizumab (Nemluvio®) for moderate to severe atopic dermatitis in people 12 years and over
TA1080 – July 2025 - Mirikizumab (Omvo®) moderate to severe active Crohn's disease
TA1081 – July 2025 - Zanubrutinib (Brukinsa®) for treating relapsed or refractory mantle cell lymphoma
TA1079 – July 2025 - Fruquintinib (Fruzaqla®) previously treated metastatic colorectal cancer
TA1085 – July 2025 - Vanzacaftor-tezacaftor-deutivacaftor for cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
TA1086 – August 2025 - Ribociclib (Kisqali®) with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
TA1090 – August 2025 - Durvalumab (Imfinzi®) with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
TA1094 – August 2025 - Guselkumab for moderately to severely active ulcerative colitis
TA1095 – August 2025 - Guselkumab for previously treated moderately to severely active Crohn's disease
TA1092 – August 2025 - Pembrolizumab (Keytruda®) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
TA1093 – August 2025 - Idebenone (Raxone®) for visual impairment in Leber's hereditary optic neuropathy in people 12 years and over
TA1096 – September 2025 - Benralizumab (Fasenra®) for relapsing or refractory eosinophilic granulomatosis with polyangiitis
TA1097 – September 2025 - Enfortumab vedotin (Padcev®) with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
TA1098 – September 2025 - Isatuximab (Sarclisa®) in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
TA1099 – October 2025 - Durvalumab (Imfinzi®) for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

GREEN	TA1075 – July 2025 (replaces TA775) - Dapagliflozin (Forxiga®) for treating chronic kidney disease
AMBER INITIATE	TA753 – December 2021, updated July 2025 - Cenobamate (Ontozry®) for treating focal onset seizures in epilepsy
	TA1087 – August 2025 - Betula verrucosa (Itulazax 12 SQ-Bet®) for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
BLACK	TA1088 – August 2025 - Ruxolitinib (Opzelura®) cream for treating non-segmental vitiligo in people 12 years and over
	TA1091 – August 2025 - Tarlatamab (IMDYLLTRA®) for extensive-stage small-cell lung cancer after 2 or more treatments
	TA1076 – July 2025 Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
	TA1082 – July 2025 Letermovir for preventing cytomegalovirus infection after a kidney transplant
	TA1083 – July 2025 Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable
	TA1084 – July 2025 Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments
	TA1089 – August 2025 Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments
	TA1100 – October 2025 Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)

Useful Information	
Next TAG meeting	Wednesday 4th November 2025
Deadline for agenda items	Tuesday 28th October 2025
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – MO Team pages	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)
• Please remember to check both KNoW and Netformulary for regular formulary updates • If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net	